- Home
- PRAX
as 12-18-2024 11:41am EST
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 1.5B | IPO Year: | 2020 |
| Target Price: | $146.33 | AVG Volume (30 days): | 315.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.08 - $86.93 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,605,000 | Revenue Growth: | -16.93% |
| Revenue Growth (this year): | -39.19% | Revenue Growth (next year): | -35.02% |
Latest Praxis Precision Medicines Inc. News
PRAX Breaking Stock News: Dive into PRAX Ticker-Specific Updates for Smart Investing
MT Newswires
3 hours ago
Praxis Says FDA Grants Rare Pediatric Disease Designation to Relutrigine to Treat Dravet Syndrome
GlobeNewswire
4 hours ago
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
GlobeNewswire
15 days ago
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
GlobeNewswire
22 days ago
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Simply Wall St.
a month ago
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
a month ago
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...
GlobeNewswire
a month ago
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
MT Newswires
a month ago
Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating
Compare PRAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRAX Praxis Precision Medicines Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.